AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
19.62
+0.04 (0.20%)
At close: May 9, 2025, 4:00 PM
19.90
+0.28 (1.43%)
After-hours: May 9, 2025, 7:06 PM EDT
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$822,588
Profits / Employee
-$1,034,000
Market Cap
575.56M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANAB News
- 5 days ago - Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Stock Repurchase Plan - GlobeNewsWire
- 2 months ago - Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Anaptys Announces Participation in March Investor Conferences - GlobeNewsWire
- 3 months ago - Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - GlobeNewsWire
- 3 months ago - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - GlobeNewsWire
- 3 months ago - Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - GlobeNewsWire